



November 7, 2017

## Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- [Five Prime Therapeutics, Inc.](#) (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that it will host a conference call and live audio webcast on Wednesday, November 8, 2017, at 8:00 a.m. (ET) to review data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, [cabiralizumab \(FPA008\)](#), with Opdivo® (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor. An abstract of the data has been selected for a late-breaking oral presentation on Saturday, November 11, 2017, at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting in National Harbor, Maryland. The late-breaking abstracts were published today by SITC.

Five Prime originally intended to host the call and webcast on November 7, 2017, but an extended GlobeNewswire outage prevented a press release from being issued. In advance of the event tomorrow, Five Prime will file a Current Report on Form 8-K with the Securities and Exchange Commission that will include the slides to accompany the conference call presentation and discussion. Five Prime's management will provide important additional details during the call.

The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at [www.fiveprime.com](http://www.fiveprime.com). Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 8687899.

The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

### About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit [www.fiveprime.com](http://www.fiveprime.com).

View source version on [businesswire.com](http://businesswire.com): <http://www.businesswire.com/news/home/20171107006912/en/>

Investor Relations Advisory Solutions  
Derek Cole, 720-785-4497  
[derek.cole@iradvisory.com](mailto:derek.cole@iradvisory.com)

Source: Five Prime Therapeutics, Inc.

News Provided by Acquire Media